Clinical Trial Update: A Phase I, 2-part (Part 1 Being a Single Dose Escalation and Part 2, a Parallel Group) Study of Toll-like Receptor (TLR4) Agonist (GSK1795091) in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase I trial of TLR4 agonist GSK1795091 in healthy subjects completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Neoplasms

Drugs mentioned

• GSK1795091

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer, Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2019-06-10